Abiopharma

Communiqué de presse : Sanofi lance son plan mondial 2026 d’actionnariat salarié

WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland

Expro Strengthens Longstanding Partnership With Deployment of Solus™ Technology in the Gulf of America

Alvotech leggur inn að nýju umsóknir um markaðsleyfi í Bandaríkjunum fyrir hliðstæður við Simponi, Simponi Aria og Eylea

111, Inc. Announces First Quarter 2026 Unaudited Financial Results

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Register of shareholders, changes and capital status – exercise of warrants for shares (unlisted) by employees

Shelf offering report for the issuance of BONDS C, according to the shelf prospectus dated 29.8.23, orders: 4.6.26